Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Aluminum – calcium or magnesium element – or compound containing
Reexamination Certificate
2002-03-26
2004-01-13
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Aluminum, calcium or magnesium element, or compound containing
C424S692000, C424S715000, C424S725000, C424S750000
Reexamination Certificate
active
06676974
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates a hexane bioactive fraction and obtained from the roots of an aromatic plant named
Vetiveria zizanioides
commonly found in India for inhibiting the growth of drug resistant bacterial infections in humans and animals. The invention also relates to a pharmaceutical composition comprising the bioactive extract with other additives for inhibiting the growth of drug resistant bacterial infections in humans and animals. The present invention also provides a process for the isolation of said bioactive extract.
BACKGROUND OF INVENTION
Antibiotics have been used for long to cure bacterial, fungal and other infectious diseases of humans. Penicillin was the first antibiotic used against infections during the Second World War. Since then a number of antibiotics and their derivatives have been identified and used by man almost all of which were isolated from microbial sources. All the antibiotics in clinical use today can be grouped or classified according to their structure or functional groups. Streptomycin, kanamycin, tetracycline some of the well-known examples are aminoglycosides whereas penicillin and its derivatives are beta-lactam antibiotics. One of the commonly used antibacterials are quinolones or fluoroquinolones such as nalidixic acid, ciprofloxacin, norfloxacin etc. Fluoroquinolones are now widely used to treat urinary tract infections, upper respiratory tract infections, and tuberculosis, which are resistant to first-line drugs. However, many of the pathogenic bacteria such as
Haemophilus influenzae
, Neisseria Sp.,
Staphylococcus aureus, Escherichia coli
are developing resistance to fluoroquinolone class of antibiotics limiting their clinical usefulness. Since, the mechanism of action of all the quinolones against bacteria is similar, development of resistance to one of the quinolone antibiotic would confer simultaneous cross-resistance to almost all the other quinolones also. Fluoroquinolones act by inhibiting the function of a bacterial enzyme DNA gyrase essential for the maintenance of supercoil nature of the bacterial chromosome. Resistance development is observed when a mutation in the DNA gyrase enzyme A subunit (GyrA+) specifically in the region called “Quinolone Determining Region (QDR)” occurs. The modified mutant form of A subunit (GyrA−) is incapable of binding to quinolone antibiotics and therefore is resistant. Such quinolone resistant infections are particularly difficult to cure. Kumar et al (
Phytotherapy Research
14: 14-15, 2000; U.S. Pat. No. 6,127,405) have identified a semi-synthetic plant compound &agr;-arteether which is capable of specifically killing quinolone drug resistant bacterial infections. The &agr;-arteether was obtained by etherification of artemissinin a sesquiterpene lactone compound from a Chinese medicinal plant
Artemisia annua
. In our effort to isolate and identify more potent plant compounds which are active against quinolone resistant bacteria we carried out a systematic bioactivity guided fractionation of the ethanolic extract prepared from the roots of Indian medicinal plant
Vetiveria zizanioides
. The subject mentioned below specifically describes the manner in which the compound inhibiting quinolone resistant bacteria was isolated and identified.
OBJECTS OF THE INVENTION
The main object of the invention is to develop a novel anti bacterial agent inhibiting the growth of multi drug resistant bacterial pathogens.
Another object of the invention is to provide a bioactive fraction from the roots of plant
Vetiveria zizanioides.
Another object of the invention is to provide a pharmaceutical composition comprising bioactive fraction or plant extract obtained from plant
Vetiveria zizanioides
Still another object of the invention is to provide a method of isolation of bioactive fraction from the roots of plant
Vetiveria zizanioides.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a bioactive hexane fraction named as CIM 109 obtained from the roots of plant
Vetiveria zizanioides
for inhibiting growth of multidrug resistant bacterial pathogens. The present invention also provides a pharmaceutical composition comprising bioactive fraction CIM 109 or plant extract or lyophilised extract to provide anti bacterial activity.
DETAILED DESCRIPTION OF INVENTION
Accordingly, the present invention provides a bioactive hexane fraction CIM 109 obtained from the plant
Vetiveria zizaniodes
having inhibitory activity against multi drug resistant bacterial pathogens.
One embodiment of the invention, the said bioactive fraction inhibits the growth of bacterial pathogens which are resistant to nalidixic acid, oxolinic acid, sparfloxicin, ciprofloxicin, lomefloxicin and any other quinolones.
Another embodiment of the invention, the multidrug resistant bacteria is selected from the group consisting of genus Mycobacterium or
Escherchia coli
preferably selected from group consisting of
Mucobacterium smegmatis
MC
2
155
, Pseudomonas aeruginosa, Bacillus subtilis
MTCC-121
, Mucobacterium smegmatis
MC
2
155 Wld type,
Mucobacterium smegmatis
MC
2
155 (NaiR) 6b,
Mucobacterium smegmatis
MC
2
155 13a and
E.Coli
DH5a.
One more embodiment of the invention relates to a pharmaceutical composition for inhibiting the growth of the bacterial pathogens, comprising effective amount of bioactive fraction named CIM-109 or partially purified extract or lyophilised extract, obtained from the plant
Vetiveria zizanioides.
Another embodiment of the invention, the composition containing the said bioactive fraction is used singly or in combination thereof to the patient.
Still another embodiment, the composition may be administered systematically or orally and preferably orally.
Still another embodiment, the bioactive fraction is administered to the patient in combination with a pharmaceutically acceptable additives carriers, diluent, solvent, filter, lubricant, excipient, binder or stabiliser.
Yet another embodiment relates to the additive used which is selected from a group consisting of citric acid, calcium carbonate, magnesium hydroxide gel and/or gel and/or lactose.
Yet another embodiment relates to amount of active fraction in the composition is in the range of 100 mg to 500 mg.
Yet another embodiment of the invention relates to amount of composition administered to a subject is in the range of 500 mg to 1000 mg per day.
Yet another embodiment of the invention relates to amount of composition administered to a subject is preferably in the range of 150 mg to 700 mg per day.
Yet another embodiment of the invention, the subject is selected mammals, animals preferably humans.
In another embodiment of the invention provides a pharmaceutical composition useful for treating fluoroquinolone resistant bacterial infections including entenc and systemic infections, said composition comprising 10 to 50% by wt of root extract of vetiver, 0.4 to 1% by wt of citric acid, 10 to 20% by wt of calcium carbonate, 10 to 20% by wt of magnesium hydroxide gel, 20 to 60% by weight of lactose and optionally comprising other pharmaceutically acceptable additives. The above said composition can optionally compounded with honey by dispersing the constituents in honey.
One more embodiment of the invention relates to a method of treating patients with bacterial infection said method comprising administering a pharmaceutically effective dosage of bioactive fraction or a formulation comprising bioactive fraction or lyophilized extract of plant
Vetiveria zizanioides
thereof to the patient.
Another embodiment of the invention relates to a process for the isolation of bioactive fraction from the plant
Vetiveria zizaniodes
having inhibitory activity against multi drug resistant bacterial pathogens, the said process comprises steps of:
a) powdering the plant part of
Vetivera Zizanioides,
b) extracting the plant powder of step (a) by soaking in protic aqueous organic solvent for a period of 16-20 hours,
c) filtering the organic solvent extract of step (b),
d) evaporating the extract of step (c) und
Bahl Janak Raj
Darokar Mahendra Pandurang
Gupta Madan Mohan
Khanuja Suman Preet Singh
Kumar Sushil
Council of Scientific and Industrial Research
Lilling Herbert J.
Nixon & Peabody LLP
Studebaker Donald R.
LandOfFree
Bioactive hexane fraction from Vetiveria zizanioides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bioactive hexane fraction from Vetiveria zizanioides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bioactive hexane fraction from Vetiveria zizanioides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3188418